ERBB2 and breast carcinoma: About 70% of breast cancers are ERα positive, while 15% to 30% of human breast tumors exhibit overexpression of HER-2 in clinical subgroups, and both of these factors raise HIF-α levels by boosting PI3K/Akt/mTOR signaling [34,35].